LOSTRILE  50 – 100  (Film Coated Tablets)

 

Composition:
Each film coated tablet contains 56 or 112mg Sertraline hydrochloride equivalent to 50 or 100mg Sertraline Base.

Properties:
Lostrile is antidepressant agent, which specifically increase serotonin levels in brain and treat the depressive illness symptoms.

Mechanism of action:
Lostrile is a potent and specific inhibitor of neuronal serotonin (5-HT) re-uptake, but is without affinity for: muscarinic, dopaminergic, adrenergic, histaminergic, or GABA receptors.

Indications:
Lostrile is indicated for the treatment of depressive illness symptoms.

Dosage and administration:

  • Initial dose: 50mg daily as a single daily dose with or without food.
  • Maintenance dose: In patients with incomplete response but good toleration at lower doses, dosage adjustments should be made in 50mg increments over a period of weeks to a maximum of 200mg daily. Once optimal therapeutic response is achieved the dose should be reduced, depending on therapeutic response, to the lowest effective level.
  • Maximum dose: 150mg or more should not be used for periods exceeding 8 weeks.

Side Effects:
Some of these side effects could be occurred: Nausea, diarrhoea, dyspepsia, tremor, dizziness, insomnia, somnolence, increased sweating, dry mouth and rash. Asymptomatic elevations in serum transaminases (AST and ALT) have been reported infrequently in association with administration. The abnormalities usually occurred within the first weeks (1 to 9 weeks) of drug treatment and promptly diminished upon drug discontinuation.

ContraIndications:
Hypersensitivity to Sertraline, patients taking monoamine oxidase inhibitors.

Drug Interactions:
It should not be used in combination with MOA inhibitors.
Lostrile interact with other plasma protein bound drug such as: Cimetidine, diazepam.
Co-administration of Lostrile (200mg daily) with warfarin resulted in an increase in warfarin effect, so the dosage should be adjusted.

Precautions:

  • As with other antidepressants, activation of mania/hypomania has been reported in a small proportion of patients.
  • Use of product should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored. The drug should be discontinued in any patient who develops seizures.
  • Caution is advised when treating patients with renal or hepatic impairment.
  • The use of product in children is not recommended.

Use in Pregnancy or Lactation:
Lostrile should be used during pregnancy only if the perceived benefits outweigh the risks. It is not recommended to be used during lactation.

Presentation:
Carton pack contains 2 blisters each of 10 film coated tablets of 50 or 100mg, with leaflet.

 

 
 
 

© 2010 Domina Pharmaceuticals